Aim To monitor a series of thirty consecutive patients receiving their first dose of intravenous immunoglobulin for haemolytic anaemia.

Methods Prospectively, thirty consecutive patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) receiving their first high dose of immunoglobulin therapy were monitored for clinical and laboratory features of haemolytic anaemia.

Results Three patients were identified with features suggestive for haemolysis.

Conclusion We confirm the literature findings of a strong association between high dose intravenous immunoglobulin therapy and haemolysis in neurology patients receiving immunoglobulin therapy.